Urology Denial Appeal

Denials in urology frequently target minimally invasive treatments for benign prostatic hyperplasia, where a plan labels the procedure investigational or requires a documented trial of medical therapy first. These procedures are FDA-cleared and supported in AUA guidance for appropriate patients, so the appeal usually turns on documenting the failed or contraindicated medical therapy and mapping the indication to the plan's criteria — not on whether the treatment is legitimate.

Why these denials happen

Plans gate minimally invasive BPH procedures with an 'investigational/not medically necessary' determination or a step requirement (a documented trial of alpha-blockers or 5-ARIs first), plus symptom-severity and prostate-anatomy criteria. AUA guidance supports these procedures for the right candidates. The denial is generally a documentation gap — the medication trail, the symptom scores, or the anatomy isn't mapped to the plan's policy — rather than a categorical exclusion.

The common denials

Procedure labeled investigational or experimental despite FDA clearance and guideline support.
Step therapy: a documented trial of medical therapy (alpha-blockers, 5-ARIs) not established or contraindicated.
Symptom-severity scores or prostate-anatomy criteria not documented to the policy.
Prior authorization missing or incomplete.
Coding or bundling edits (a separate, correctable issue — not a medical-necessity appeal).

Is it worth appealing?

Sometimes worth appealing

Worth appealing when the indication is documentable: the failed or contraindicated medical therapy, the symptom scores, and the anatomy, mapped to the plan's policy and AUA guidance. For an 'investigational' denial, cite the FDA clearance and the guideline support for the specific candidate. A documented intolerance to medical therapy counts as a satisfied step. Separate true medical-necessity denials from coding edits, which are corrected rather than appealed.

How to appeal

1
Answer the 'investigational' label directly
Cite the procedure's FDA clearance and AUA guideline support for the patient's candidacy — an 'investigational' denial is a medical-necessity question, not a closed door.
2
Document the therapy trail
Show the trial, failure, intolerance, or contraindication of medical therapy the plan requires, with the symptom scores that establish severity.
3
Separate coding from medical necessity
If the denial is a modifier or bundling edit, correct the claim rather than running a clinical appeal.

Frequently asked

The plan called my UroLift/Rezūm 'investigational' — can I appeal?

Yes. These procedures are FDA-cleared and supported in AUA guidance for appropriate patients. Frame the appeal as medical necessity: cite the clearance and guideline support and document the patient's candidacy and prior therapy.

They want me to try medication first. Is that appealable?

It's a step-therapy denial. Document the trial and failure — or the intolerance or contraindication, which counts as a met step — and map the symptom severity to the plan's criteria.

Sources

Clinical-coverage patterns and guideline references are summarized for plain-language reference and vary by plan and payer policy. This is general information for clinicians and billing staff, not medical, legal, or coding advice — confirm against the governing coverage policy and the current guideline for each claim.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →